Literature DB >> 30249743

Comparative Analysis of the Capacity of the Candida Species To Elicit Vaginal Immunopathology.

Hubertine M E Willems1, David J Lowes1, Katherine S Barker1, Glen E Palmer1, Brian M Peters2.   

Abstract

The human fungal pathogen Candida albicans is the major etiological agent of vulvovaginal candidiasis (VVC). Despite this fact, other non-albicans Candida (NAC) species have frequently been reported, as well. Despite their presence in the vaginal environment, little is known about their capacities to elicit immune responses classically associated with C. albicans-mediated immunopathology, including neutrophil recruitment and proinflammatory cytokine signaling. Therefore, using a combination of in vitro and in vivo approaches, we undertook a comparative analysis to determine whether a representative panel of NAC species could colonize, induce immunopathological markers, or cause damage at the vaginal mucosa. Using a murine model of VVC, C. albicans was found to induce robust immunopathology (neutrophils and interleukin 1β [IL-1β]) and elicit mucosal damage. However, all the NAC species tested (including C. dubliniensis, C. tropicalis, C. parapsilosis, C. krusei, C. glabrata, and C. auris) induced significantly less damage and neutrophil recruitment than C. albicans, despite achieving similar early colonization levels. These results largely correlated with a notable lack of ability by the NAC species (including C. dubliniensis and C. tropicalis) to form hyphae both in vitro and in vivo Furthermore, both C. dubliniensis and C. tropicalis induced significantly less expression of the ECE1 gene encoding candidalysin, a key fungal virulence determinant driving VVC immunopathology. In order to determine the relative capacities of these species to elicit inflammasome-dependent IL-1β release, both wild-type and NLRP3-/- THP-1 cells were challenged in vitro While most species tested elicited only modest amounts of IL-1β, challenge with C. albicans led to significantly elevated levels that were largely NLRP3 dependent. Collectively, our findings demonstrate that although NAC species are increasingly reported as causative agents of VVC, C. albicans appears to be exceedingly vaginopathogenic, exhibiting robust immunopathology, hypha formation, and candidalysin expression. Thus, this study provides mechanistic insight into why C. albicans is overwhelmingly the major pathogen reported during VVC.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Candidazzm321990; NAC species; VVC; immunopathogenesis; inflammasome; vaginitis; vulvovaginal

Mesh:

Substances:

Year:  2018        PMID: 30249743      PMCID: PMC6246903          DOI: 10.1128/IAI.00527-18

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  64 in total

1.  Vulvovaginal candidiasis in a Flemish patient population.

Authors:  M M De Vos; M Cuenca-Estrella; T Boekhout; B Theelen; N Matthijs; T Bauters; H Nailis; M A Dhont; J L Rodriguez-Tudela; H J Nelis
Journal:  Clin Microbiol Infect       Date:  2005-12       Impact factor: 8.067

2.  Comparison Between Virulence Factors of Candida albicans and Non-Albicans Species of Candida Isolated from Genitourinary Tract.

Authors:  Shani Jacob; Diney D'Souza
Journal:  J Clin Diagn Res       Date:  2014-11-20

3.  Molecular identification and antifungal susceptibility of 186 Candida isolates from vulvovaginal candidiasis in southern China.

Authors:  Xiao-Yu Shi; Yan-Ping Yang; Ying Zhang; Wen Li; Jie-Di Wang; Wen-Ming Huang; Yi-Ming Fan
Journal:  J Med Microbiol       Date:  2015-01-16       Impact factor: 2.472

4.  Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis.

Authors:  Dharmendra Kumar; Tuhina Banerjee; Chandra Bhan Pratap; Ragini Tilak
Journal:  J Infect Dev Ctries       Date:  2015-04-15       Impact factor: 0.968

5.  Prevalence of and risk factors for fungal vaginitis caused by non-albicans species.

Authors:  A Spinillo; E Capuzzo; R Gulminetti; P Marone; L Colonna; G Piazzi
Journal:  Am J Obstet Gynecol       Date:  1997-01       Impact factor: 8.661

6.  Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp1.

Authors:  J F Staab; S D Bradway; P L Fidel; P Sundstrom
Journal:  Science       Date:  1999-03-05       Impact factor: 47.728

7.  Fungal Profile of Vulvovaginal Candidiasis in a Tertiary Care Hospital.

Authors:  Krishnapriya Kalaiarasan; Rakesh Singh; Latha Chaturvedula
Journal:  J Clin Diagn Res       Date:  2017-03-01

8.  Candidalysin Drives Epithelial Signaling, Neutrophil Recruitment, and Immunopathology at the Vaginal Mucosa.

Authors:  Jonathan P Richardson; Hubertine M E Willems; David L Moyes; Saeed Shoaie; Katherine S Barker; Shir Lynn Tan; Glen E Palmer; Bernhard Hube; Julian R Naglik; Brian M Peters
Journal:  Infect Immun       Date:  2018-01-22       Impact factor: 3.441

9.  Candida albicans yeast and hyphae are discriminated by MAPK signaling in vaginal epithelial cells.

Authors:  David L Moyes; Celia Murciano; Manohursingh Runglall; Ayesha Islam; Selvam Thavaraj; Julian R Naglik
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

10.  Specific pathways mediating inflammasome activation by Candida parapsilosis.

Authors:  Adél Tóth; Erik Zajta; Katalin Csonka; Csaba Vágvölgyi; Mihai G Netea; Attila Gácser
Journal:  Sci Rep       Date:  2017-02-22       Impact factor: 4.379

View more
  10 in total

1.  Vulvovaginal Candida albicans Clinical Isolates' Resistance to Phagocytosis In-Vitro.

Authors:  Paula Faria-Gonçalves; Ana Sofia Oliveira; Carlos Gaspar; Lisa Rodrigues; Rita Palmeira-de-Oliveira; José Martinez-de-Oliveira; Teresa Gonçalves; Ana Palmeira-de-Oliveira; Joana Rolo
Journal:  Life (Basel)       Date:  2022-06-04

Review 2.  Vulvovaginal Candidiasis: A Current Understanding and Burning Questions.

Authors:  Hubertine M E Willems; Salman S Ahmed; Junyan Liu; Zhenbo Xu; Brian M Peters
Journal:  J Fungi (Basel)       Date:  2020-02-25

Review 3.  Applying the Host-Microbe Damage Response Framework to Candida Pathogenesis: Current and Prospective Strategies to Reduce Damage.

Authors:  Paul L Fidel; Junko Yano; Shannon K Esher; Mairi C Noverr
Journal:  J Fungi (Basel)       Date:  2020-03-11

Review 4.  Pathogenesis and Clinical Relevance of Candida Biofilms in Vulvovaginal Candidiasis.

Authors:  Carmen Rodríguez-Cerdeira; Erick Martínez-Herrera; Miguel Carnero-Gregorio; Adriana López-Barcenas; Gabriella Fabbrocini; Monika Fida; May El-Samahy; José Luís González-Cespón
Journal:  Front Microbiol       Date:  2020-11-11       Impact factor: 5.640

5.  Candidalysins Are a New Family of Cytolytic Fungal Peptide Toxins.

Authors:  Jonathan P Richardson; Rhys Brown; Nessim Kichik; Sejeong Lee; Emily Priest; Selene Mogavero; Corinne Maufrais; Don N Wickramasinghe; Antzela Tsavou; Natalia K Kotowicz; Olivia W Hepworth; Ana Gallego-Cortés; Nicole O Ponde; Jemima Ho; David L Moyes; Duncan Wilson; Christophe D'Enfert; Bernhard Hube; Julian R Naglik
Journal:  mBio       Date:  2022-01-25       Impact factor: 7.867

6.  α-galactosylceramide-stimulated invariant natural killer T-cells play a protective role in murine vulvovaginal candidiasis by Candida albicans.

Authors:  Masahiro Abe; Yuki Kinjo; Sota Sadamoto; Minoru Shinozaki; Minoru Nagi; Kazutoshi Shibuya; Yoshitsugu Miyazaki
Journal:  PLoS One       Date:  2021-11-16       Impact factor: 3.240

7.  An Exaggerated Monocyte-Derived Cytokine Response to Candida Hyphae in Patients With Recurrent Vulvovaginal Candidiasis.

Authors:  Diletta Rosati; Mariolina Bruno; Martin Jaeger; Bart-Jan Kullberg; Frank van de Veerdonk; Mihai G Netea; Jaap Ten Oever
Journal:  J Infect Dis       Date:  2022-05-16       Impact factor: 7.759

8.  Divergent EGFR/MAPK-Mediated Immune Responses to Clinical Candida Pathogens in Vulvovaginal Candidiasis.

Authors:  Jingyun Zhang; Jingwen Peng; Dongmei Li; Huan Mei; Yu Yu; Xiaofang Li; Xiaodong She; Weida Liu
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

9.  Second-Generation Antidiabetic Sulfonylureas Inhibit Candida albicans and Candidalysin-Mediated Activation of the NLRP3 Inflammasome.

Authors:  David J Lowes; Kirk E Hevener; Brian M Peters
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 10.  It Takes Two to Tango: How a Dysregulation of the Innate Immunity, Coupled With Candida Virulence, Triggers VVC Onset.

Authors:  Andrea Ardizzoni; Robert T Wheeler; Eva Pericolini
Journal:  Front Microbiol       Date:  2021-06-07       Impact factor: 6.064

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.